In the Keynote trials, therapy was continued for 2 years. With a median progression free survival of approximately 8 months, the number of patients who are able to continue therapy for 2 years is small. However, if a patient does stay on therapy I follow the protocol and recommend stopping therapy a...

This is a great question! The optimal duration of maintenance therapy remains undefined. In my practice, most patients receive carboplatin plus pemetrexed plus pembrolizumab as 1st line therapy if they have advanced non-squamous non-small cell lung cancer. I usually treat with this 3 drug regimen fo...

I pretty much agree with @Nasser H. Hanna. When it comes to maintenance therapy, I abide by the KN 189 trial, for the most part: 4 cycles of the triplet, followed by maintenance Pemetrexed/Pembrolizumab for at least two years. At that point, unless there is some compelling reason to do otherwise, I ...